Participation of critical residues from the extreme C-terminal end of the human androgen receptor in the ligand binding function

被引:20
作者
Tahiri, B [1 ]
Auzou, G [1 ]
Nicolas, JC [1 ]
Sultan, C [1 ]
Lupo, B [1 ]
机构
[1] INSERM, U439, F-34090 Montpellier, France
关键词
D O I
10.1021/bi010146q
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A Short C-terminal end is present at the end of the human androgen receptor (hAR) similar to that of other steroid receptors. It is located directly after helix 12 of the ligand binding domain and has never been described as being part of the hydrophobic binding pocket. Although some fragmentary data have indicated the involvement of this region in ligand binding, its precise function still remains unclear. To gain deeper insight into the role of the hAR extreme C-terminal end, an extensive mutational analysis was carried out by using site-directed mutagenesis and alanine scanning over the 13-residue C-terminal end region. Both ligand binding and transcriptional activity were tested with each mutant. Our study demonstrates the participation of almost all of the amino acids in this region for the ligand binding function and consequently for the transcriptional activity. A conformational study by limited proteolysis was performed with the mutants that most affected the affinity of the receptor. It was remarkable that the mutants with a low binding affinity adopted an inactive conformation and were either less or not able to undergo a following conformational change to provide the active form of the receptor. Our results demonstrate the importance of hydrophobicity for the function of the C-terminal end with residues located at very precise positions. Especially, both hydrophobicity and aromaticity on position 916 are critical for providing the correct ligand binding conformation of the receptor. Furthermore, this study highlights essential criteria regarding the C-terminal amino acids which could be applied to other steroid receptors.
引用
收藏
页码:8431 / 8437
页数:7
相关论文
共 37 条
[21]   Structural evidence for ligand specificity in the binding domain of the human androgen receptor -: Implications for pathogenic gene mutations [J].
Matias, PM ;
Donner, P ;
Coelho, R ;
Thomaz, M ;
Peixoto, C ;
Macedo, S ;
Otto, N ;
Joschko, S ;
Scholz, P ;
Wegg, A ;
Bäsler, S ;
Schäfer, M ;
Egner, U ;
Carrondo, MA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (34) :26164-26171
[22]   AMINO/AROMATIC INTERACTIONS IN PROTEINS - IS THE EVIDENCE STACKED AGAINST HYDROGEN-BONDING [J].
MITCHELL, JBO ;
NANDI, CL ;
MCDONALD, IK ;
THORNTON, JM ;
PRICE, SL .
JOURNAL OF MOLECULAR BIOLOGY, 1994, 239 (02) :315-331
[23]  
NAZARETH LV, 1997, 79 US END SOC M JUL
[24]   Specific recognition of androgens by their nuclear receptor - A structure-function study [J].
Poujol, N ;
Wurtz, JM ;
Tahiri, B ;
Lumbroso, S ;
Nicolas, JC ;
Moras, D ;
Sultan, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (31) :24022-24031
[25]   Androgen receptor point mutations as the underlying molecular defect in 2 patients with androgen insensitivity syndrome [J].
Radmayr, C ;
Culig, Z ;
Glatzl, J ;
NeuschmidKaspar, F ;
Bartsch, G ;
Klocker, H .
JOURNAL OF UROLOGY, 1997, 158 (04) :1553-1556
[26]  
SAMBROOK J, 1989, MOL CLONING LAB HDB
[27]   CELL-SPECIFIC INHIBITORY AND STIMULATORY EFFECTS OF FOS AND JUN ON TRANSCRIPTION ACTIVATION BY NUCLEAR RECEPTORS [J].
SHEMSHEDINI, L ;
KNAUTHE, R ;
SASSONECORSI, P ;
PORNON, A ;
GRONEMEYER, H .
EMBO JOURNAL, 1991, 10 (12) :3839-3849
[28]  
TAKAHASHI H, 1995, CANCER RES, V55, P1621
[29]  
TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315
[30]   CHARACTERIZATION OF POLYCLONAL ANTIBODIES AGAINST THE N-TERMINAL DOMAIN OF THE HUMAN ANDROGEN RECEPTOR [J].
VANLAAR, JH ;
VOORHORSTOGINK, MM ;
ZEGERS, ND ;
BOERSMA, WJA ;
CLAASSEN, E ;
VANDERKORPUT, JAGM ;
DEWINTER, JAR ;
VANDERKWAST, TH ;
MULDER, E ;
TRAPMAN, J ;
BRINKMANN, AO .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1989, 67 (01) :29-38